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Abstract We tested a panel of naturally occurring nucleo-
sides for their affinity towards adenosine receptors. Both N
6-
(2-isopentenyl)adenosine (IPA) and racemic zeatin riboside
were shown to be selective human adenosine A3 receptor
(hA3R) ligands with affinities in the high nanomolar range
(Ki values of 159 and 649 nM, respectively). These values
were comparable to the observed Ki value of adenosine on
hA3R, which was 847 nM in the same radioligand binding
assay. IP A also bound with micromolar affinity to the rat
A3R. In a functional assay in Chinese hamster ovary cells
transfected with hA3R, IP A and zeatin riboside inhibited
forskolin-induced cAMP formation at micromolar potencies.
The effect of IP A could be blocked by the A3Ra n t a g o n i s t
VUF5574. Both IP A and reference A3R agonist 2-chloro-N
6-
(3-iodobenzyl)adenosine-5′-N-methylcarboxamide (Cl-IB-
MECA) have known antitumor effects. We demonstrated
strong and highly similar antiproliferative effects of IP A and
Cl-IB-MECA on human and rat tumor cell lines LNCaP and
N1S1. Importantly, the antiproliferative effect of low
concentrations of IP A on LNCaP cells could be fully blocked
by the selective A3R antagonist MRS1523. At higher
concentrations, IP A appeared to inhibit cell growth by an
A3R-independent mechanism, as was previously reported for
other A3R agonists. We used HPLC to investigate the
presence of endogenous IP A in rat muscle tissue, but we
could not detect the compound. In conclusion, the anti-
proliferative effects of the naturally occurring nucleoside IP A
are at least in part mediated by the A3R.
Keywords Adenosine A3 receptor.N
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Introduction
Four adenosine receptors have been cloned and pharmaco-
logically characterized: A1,A 2A,A 2B, and A3. Of these
subtypes, the A3R has been identified last [1]. The hA3R
has a wide distribution in the body. High expression is
observed in liver, lungs, and immune cells, whereas the
brain, testes, placenta, and heart display moderate expres-
sion levels [2, 3]. Furthermore, a very high expression level
is observed in tumor cell lines and cancer tissues, making
the A3R an interesting target for the treatment of cancer (for
a review, see [4]). A recent study even showed that the
threefold A3R upregulation in human colorectal cancer was
reflected, via an unknown mechanism, in peripheral blood
cells [5]. This could make the A3R a promising biomarker
for this and possibly other types of cancer. We and others
have previously shown that A3R agonists have antiprolifer-
ative effects on tumor cells in vitro and in vivo,
characterized by induction of G0/G1 cell cycle arrest and
apoptosis [4]. It has been shown that, in most cases, a
deregulation of the NF-κB and Wnt signaling pathways is
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may be more important in specific cell types. For example,
in A375 human melanoma cells, A3R stimulation activated
phosphatidylinositol 3-kinase (PI3K) which induced Akt
phosphorylation, finally resulting in reduced levels of
phosphorylated extracellular signal-regulated kinase 1/2
(ERK1/2) [6]. Another recent study suggested that A3R
upregulation may precede asbestos-induced malignant
mesothelioma formation [7]. The A3R agonist 2-chloro-
N
6-(3-iodobenzyl)adenosine-5′-N-methylcarboxamide (Cl-
IB-MECA) prevented TNF-α-mediated cell survival after
asbestos exposure in vitro by acting on the deregulated Akt/
NF-κB pathways, showing that A3R is a possible target for
cancer prevention as well as treatment. Interestingly, A3R
agonists do not inhibit the growth of normal cells [7–9].
Moreover, these ligands can act as cytoprotective agents,
for example by preventing the myelotoxic effects of
chemotherapy [10]. In view of the promising preclinical
data, the safety profile of the A3R agonist IB-MECA has
been evaluated in phase I clinical studies [11]. This agonist
was tolerated very well. Related A3R agonist Cl-IB-MECA
is currently in phase I/II clinical trials for hepatocellular
carcinoma ([12] and trial ID: NCT00790218).
On the basis of these studies and observations, we
hypothesized that endogenous A3R agonists might also
contribute to the body’s natural defense mechanism against
tumors. In particular, such compounds may be excreted by
striated muscle cells, protecting the tissue from metastases
[13]. We have shown that extracts from muscle cells inhibited
tumor proliferation while protecting bone marrow cells in
vivo. These effects were dependent on A3R activation.
However, they could not be attributed to adenosine, as the
effect was not sensitive to adenosine deaminase (ADA) and
could not be reproduced by administration of adenosine alone
[13]. Thus, we set out to identify other endogenous agonists
for the A3R.
In the current work, we report the affinity of a panel of
naturally occurring nucleosides for the human adenosine
receptors, while focusing on the hA3R. Then, we assessed
the potency of the two higher affinity compounds, the
nucleosides IPA and racemic zeatin riboside, in cAMP
generation assays. The effect of IPA and the reference A3R
agonist Cl-IB-MECA on tumor cell line proliferation was
also determined. We provide evidence that the antiprolifer-
ative effects of IPA are indeed linked to the A3R as they can
be partially blocked by a selective antagonist for that
receptor. We also present an HPLC method to investigate
the IPA content of muscle tissue. However, endogenous IPA
could not be detected in our analysis.
Materials and methods
Materials
[
3H]-DPCPX and [
125I]-AB-MECA were purchased from
Amersham Biosciences (Roosendaal, the Netherlands).
[
3H]-ZM241385 and [
3H]-MRS1754 were obtained from
Tocris Cookson, Ltd. (Bristol, UK). All nucleosides listed
in Table 1 were supplied by Sigma-Aldrich (Zwijndrecht,
Table 1 Chemical structures of naturally occurring modified nucleosides and their effects in radioligand binding studies at human adenosine A1,
A2A,A 2B, and A3 receptors
2 R 1 R e m a N
% displacement  Ki or %
displacement 
hA1 hA2A hA2B hA3
D N D N D N H O - H - e n i s o n e d A a 1 847±60 nM
1b N
6-(2-isopentenyl)-
adenosine (IPA)  -CH2CHC(CH3)2 -OH 14 0 0 159±19 nM
1c Trans-zeatin riboside -CH2CHC(CH3)CH2OH -OH 2 0 6 31%
1d Racemic zeatin riboside -CH2CHC(CH3)CH2OH -OH 17 0 0 643±27 nM
1e 2 H C O - H - e n i s o n e d a l y h t e m - O - 3 008 0 %
% 4 3 4 0 2 - - e n i s o n e d a - l y h t e m - 1 2
N
N
N
N
O O H
OH OH
NH
N
N
N
N
O O H
OH R2
N H
R1
1 2
Percent displacement at 1 μM( N=2) or Ki value (N=3) is shown; data are means (±SEM) of N experiments performed in duplicate
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of muscle tissue were obtained from Fluka (Zwijndrecht, the
Netherlands), whereas methanol for the HPLC analysis was
from Biosolve (V alkenswaard, the Netherlands).
Chinese hamster ovary (CHO) cells expressing the human
adenosine A1 receptor were kindly provided by Dr. A.
Townsend-Nicholson (University College of London, UK).
Human embryonic kidney (HEK) 293 cells stably expressing
the human adenosine A2A receptor were a gift from Dr. E.
Wang (Biogen/IDEC, San Diego, CA, USA). CHO cells
expressing the human adenosine A2B receptor were donated
by Dr. S. Rees (GSK, Stevenage, UK), and both CHO and
HEK293 cells expressing the hA3Rw e r ek i n d l yp r o v i d e db y
Dr. K.-N. Klotz (University of Wuerzburg, Germany). RBL-
2H3 cells were a kind gift of Dr. Frank Redegeld (Utrecht
University, the Netherlands). LNCaP (human prostate carci-
noma), and N1S1 (rat hepatocellular carcinoma) cells were
purchased from the American Type Culture Collection
(Manassas, V A, USA).
Fresh Wistar rat cadavers from an untreated control
group of another study were kindly provided by the animal
facility of the Leiden/Amsterdam Center for Drug Research
(Leiden, the Netherlands).
Radioligand binding studies
Cell culture and membrane preparation
CHO cells expressing the human A1 receptor were cultured
in a 1:1 mixture of Dulbecco’s modified Eagle’s medium
(DMEM) and Ham’s F12 medium containing 10% newborn
calf serum, streptomycin (50 μg/ml), penicillin (50 IU/ml),
and G418 (0.2 mg/ml) at 37°C and 5% CO2. HEK 293 cells
stably expressing either the human A2A adenosine receptor
or the hA3R were grown in DMEM containing 10%
newborn calf serum, streptomycin (50 μg/ml), penicillin
(50 U/ml), and G418 (0.5 mg/ml) at 37°C and 7% CO2.
Membranes were prepared as previously described [14].
ADA was added in the final preparations at 0.8 IU/ml,
except for the membranes containing the A3R, where no
ADAwas included.
Human adenosine A1 receptor
Affinity for the human A1 receptor was determined on
membranes from CHO cells expressing the human recep-
tors, using [
3H]-DPCPX as the radioligand. Membranes
containing 10 μg of protein were incubated in a total
volume of 200 μl of 50 mM Tris/HCl (pH 7.4) and [
3H]-
DPCPX (final concentration 1.6 nM) for 1 h at 25°C in a
shaking water bath. Nonspecific binding was determined in
the presence of 10 μM CPA. The incubation was terminated
by filtration over Whatman GF/B filters under reduced
pressure with a Brandell harvester. Filters were washed
three times with ice-cold buffer and placed in scintillation
vials. Packard Emulsifier Safe (3.5 ml) was added and, after
2 h incubation, radioactivity was counted in a PerkinElmer
Tri-Carb 2900 β-scintillation counter.
Human adenosine A2A receptor
Affinity for the human A2A receptor was determined on
membranes from HEK293 cells stably expressing this
receptor, using [
3H]-ZM241385 as the radioligand. Mem-
branes containing 30 μg of protein were incubated in a total
volume of 200 μl of 50 mM Tris/HCl (pH 7.4) and [
3H]-
ZM241385 (final concentration 1.7 nM) for 2 h at 25°C in a
shaking water bath. Nonspecific binding was determined in
the presence of 10 μM CGS21680. Filtration and counting
were performed as described for the A1 receptor.
Human adenosine A2B receptor
At the human A2B receptor, radioligand displacement was
determined on membranes from CHO cells stably transfected
with this receptor, using [
3H]-MRS1754 as the radioligand.
Membranes containing 20 μg of protein were incubated in a
total volume of 100 μl of 50 mM Tris/HCl (pH 7.4), 10 mM
MgCl2, 1 mM EDTA, 0.01w/v %C H A P S( p H8 . 2 6a t5 ° C ) ,
and [
3H]-MRS1754 (final concentration 1.2 nM) for 1 h at
25°C in a shaking water bath. Nonspecific binding was
determined in the presence of 1 mM NECA. Filtration and
counting were performed as described for the A1 receptor.
Human A3R
The affinity at the hA3R was measured on membranes from
HEK293 cells stably expressing this receptor, using [
125I]-AB-
MECA as the radioligand. Membranes containing 35 μgo f
protein were incubated in a total volume of 100 μlo f5 0m M
Tris/ HCl, 10 mM MgCl2,1m ME D T A ,0 . 0 1 %w/v CHAPS
(pH 8.26 at 5°C ), and [
125I]-AB-MECA (final concentration
0.10 nM) for 1 h at 37°C in a shaking water bath. Nonspecific
binding was determined in the presence of 100 μMR - P I A .
The incubation was terminated by filtration over Whatman
GF/B filters under reduced pressure with a Brandell harvester.
Filters were washed three times with ice-cold buffer and
placed in counting tubes. Radioactivity was counted in a
PerkinElmer Wallac 1470 Wizard gamma-counter.
Rat A3R
The affinity at the rat A3R was measured on membranes
from RBL-2H3 (rat basophilic leukemia) cells endogenous-
ly expressing this receptor, using [
125I]-AB-MECA as the
radioligand. Membranes of these cells were prepared as
Purinergic Signalling (2011) 7:453–462 455described previously [15]. Membranes containing 60 μgo f
protein were incubated in a total volume of 100 μlo f
50 mM Tris/ HCl, 10 mM MgCl2 (pH 7.7 at 22°C ), and
[
125I]-AB-MECA (final concentration 0.20 nM) for 1 h at
37°C in a shaking water bath. Nonspecific binding was
determined in the presence of 100 μM R-PIA. Filtration
and counting were performed as described for the hA3R.
Second messenger studies: cAMP production in cells
expressing the hA3R
CHO cells expressing the hA3R were grown overnight as a
monolayer in 24-well tissue culture plates (400 μl/well; 2×
10
5 cells/well) in a 1:1 mixture of Dulbecco’s modified
Eagle’s medium (DMEM) and Ham’s F12 medium containing
10% newborn calf serum, streptomycin (50 μg/ml), penicillin
(50 IU/ml), and G418 (0.2 mg/ml) at 37°C and 5% CO2.T o
determine the potencies of IPA, adenosine, and zeatin riboside,
cAMP generation was performed in DMEM/N-(2-hydrox-
yethyl)piperazine-N′-2-ethanesulfonic acid (HEPES) buffer
(0.60 g HEPES/50 ml DMEM, pH 7.4). Each well was
washed twice with HEPES/DMEM buffer (250 μl), after
which the PDE inhibitors rolipram (50 μM) and cilostamide
(50 μM) were added to each well. This mixture was incubated
for 30 min at 37°C followed by the introduction of either the
compound of interest (10 μM), reference compound Cl-IB-
MECA (10 μM), or DMEM/HEPES. After a further 10 min
of incubation, forskolin was added (10 μM). After a
subsequent 15 min, incubation was stopped by aspirating the
assay medium and by adding 200 μlo fi c e - c o l d0 . 1MH C l .
The amount of cAMP was determined by competition with
[
3H]-cAMP for protein kinase A (PKA). Briefly, the sample,
approximately 1.8 nM [
3H]-cAMP , and 100 μlo fP K A
solution were incubated on ice for at least 2.5 h. The
incubations were stopped by rapid dilution with 2 ml of ice-
cold Tris/ HCl buffer (50 mM, pH 7.4), and bound radioactive
material was then recovered by filtration through Whatman
GF/C filters. Filters were additionally rinsed with 2×2 ml of
Tris/HCl buffer, Packard Emulsifier Safe (3.5 ml) was added
and, after 2 h, radioactivity was counted in a PerkinElmer Tri-
Carb 2900 β-scintillation counter.
In the assays evaluating the effects of ADA and VUF5574,
intracellular cAMP levels were measured using a LANCE
cAMP 384 kit (PerkinElmer, the Netherlands) as described
previously [16]. To each well, 5 μl of the agonist Cl-IB-
MECA, adenosine, or IPA (10 μM final concentration) in
stimulation buffer (PBS with 5 mM HEPES, pH 7.4
supplemented with 0.1% BSA, rolipram (50 μM), and
cilostamide (50 μM)) was added in the absence (control) or
presence of ADA (0.8 IU/mL) or VUF5574 (1 μM). Then,
4.5 μlh A 3-CHO cell suspension in stimulation buffer was
seeded into a 384-well plate (approximately 5,000 cells/well),
which was followed by incubation for 15 min at room
temperature. Subsequently, 2.5 μlf o r s k o l i n( 1μM) was added
and the mixture was incubated for 30 min at room
temperature. Then, detection mix (6 μl) and cAMP antibody
solution (6 μl) were added and incubated for 3 h. Intracellular
cAMP levels were measured using a TR-FRET assay on a
Victor spectrometer (PerkinElmer, the Netherlands) according
to instructions of the supplier. All data reflect the average of at
least three independent experiments performed in duplicate.
Proliferation assays on tumor cell lines
Effect of IP A on the proliferation of tumor cell lines
Cell proliferation was studied in both N1S1, a rat
hepatocellular carcinoma cell line, and LNCaP , a human
prostate carcinoma cell line. The cells were grown in RPMI
1640 with penicillin (100 U/ml), streptomycin (100 μg/ml),
L-glutamine (2 mM), and 10% fetal bovine serum (FBS).
The cells were maintained in T-75 flasks at 37°C in a 5%
CO2 incubator and transferred to freshly prepared medium
twice weekly. For the in vitro studies with the LNCaP cell
line, serum-starved cells were used. In these experiments,
FBS was omitted from the culture medium for 18 h and the
experiment was carried out on monolayers of cells in RPMI
medium supplemented with 1% FBS. For the N1S1 cells,
no serum starvation was used and the assay was carried out
in the growth medium of the cells.
The cells (1.5×10
4/ml) were incubated in 96-well
microtiter plates in the presence of 25 μM adenosine or
various concentrations of Cl-IB-MECA and IPA (0.01, 0.1,
1, and 10 μM). A 24-h [
3H]-thymidine incorporation assay
was used to evaluate cell growth, except for the experi-
ments evaluating the effect of EHNA (10 μM), which lasted
48 h. For the last 18 h of incubation, each well was pulsed
with 1 μCi [
3H]-thymidine. Cells were harvested, and the
[
3H]-thymidine uptake was determined in an LKB liquid
scintillation counter (LKB, Piscataway, NJ, USA).
Effect of IP A on the proliferation of LNCaP cells
in the presence of the A3R antagonist MRS1523
The effect of IPA on the proliferation of LNCaP cells in the
presence of the A3R antagonist MRS1523 was also
examined. The cells (1.5×10
4/ml) were incubated in 96-
well microtiter plates with IPA (0.01, 0.1, 1, and 10 μM) in
the absence or presence of MRS1523 (0.01, 0.1, and
1 μM). Cell growth was evaluated in a 24-h [
3H]-thymidine
incorporation assay as described above.
Data analysis
All radioligand displacement curves and cAMP concentration–
effect curves were analyzed with GraphPad Prism software
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production assays was done using an unpaired Student’s t test.
HPLC analysis of the presence of IPA in rat muscle tissue
The presence of IP A in rat muscle tissue was investigated by
HPLC analysis. Fresh rat muscle tissue (hind leg vastus
lateralis andsemimembranosus)was used.About 5 goftissue
was weighed exactly and cut into small pieces of about 5×5×
5 mm. The material was spiked with IP A and/or internal
standard cyclopentyladenosine in methanol (2.5 μg). Then,
30 ml of 5 mM ammonium acetate (pH 5.2), 50 mM EDTA
was added, and the material was treated with a Diax 900
homogenizer (Heidolph, Schwabach, Germany) equipped
with a 1.5-cm probe, for 1.5 min at speed 1. The homogenate
was subjected to four freeze–thaw cycles in liquid nitrogen
and a 60°C water bath. The sample was centrifuged at
6,000×g at 4°C for 30 min, and the supernatant was
additionally centrifuged at 200,000×g at 4°C for 45 min.
After the centrifugation steps, the clear supernatant was
filtered over Miracloth to remove fat particles and transferred
to an activated C18 solid phase extraction column (Grace,
Deerfield, USA). After passing the sample, the column was
washed with 25 ml of 5 mM ammonium acetate, and the
material of interest was eluted with 5 ml methanol. The
methanol was evaporated in a vacuum centrifuge, and the
sample was reconstituted in 0.5 ml of 5 mM ammonium
acetate, after which HPLC analysis was performed.
The system consisted of a gradient solvent delivery
system (Gilson, Den Haag, the Netherlands), equipped with
a Gilson 115 UV detector, monitoring at 270 nm. The
column was a Discovery
® RP 18 (Supelco, Zwijndrecht, the
Netherlands), 125×4.6 mm, packed with 5 μM particles.
As eluent, a gradient between solvent A (10% methanol in
5 mM ammonium acetate) and solvent B (90% methanol in
5 mM ammonium acetate) was applied with a flow of
0.6 ml/min. The profile of the gradient was as follows:
0 min, 0% B; 10 min, 0% B; 15 min, 37.5% B; 35 min,
37.5% B; 40 min, 100% B; 50 min, 100% B; 51 min, 0%
B; and 60 min, 0% B. For analysis, 100 μl of sample in
5 mM ammonium acetate pH 5.2 was injected by an
autoinjector. Data were recorded and processed using
ADchrom software (Leiden University, the Netherlands).
Results
Radioligand binding studies on human adenosine receptors
The affinities of the naturally occurring modified nucleo-
sides 1-methyl-adenosine, 2′-O-methyl-adenosine, IPA,
trans-zeatin riboside, and racemic zeatin riboside were
determined in radioligand binding studies on all four
subtypes of human adenosine receptors (Table 1). The
affinity of adenosine for the A1,A 2A, and A2B receptors
could not be assessed in this experimental setup due to the
essential presence of ADA in the assays. Both IPA and the
racemic mixture of cis- and trans-isomers of zeatin riboside
showed affinities in the higher nanomolar range (Ki values
of 159 and 643 nM, respectively) for the hA3R, in the same
range as the affinity of adenosine itself. The affinities of
both zeatin riboside and IPA at the other adenosine receptor
subtypes were negligible, given the lack of displacement at
a test concentration of 1 μM.
Affinity of IPA for the rat A3R
The affinity of IPA for the rat A3R was also determined in
radioligand binding studies (Fig. 1). A Ki value of 4.69±
0.20 μM was found for the rat ortholog, so the affinity of
IPA for the rat A3R was lower than for the hA3R.
Effect of IPA on the cAMP production in cells expressing
the hA3R
The potency of adenosine, IPA, and racemic zeatin riboside
to modulate cAMP production was determined in intact
CHO cells stably expressing the hA3R (Table 2). Adenosine
and IPA inhibited forskolin-stimulated cAMP accumulation
with similar potencies in the low micromolar range and
virtually identical intrinsic activities.
In a second assay, the effects of ADA and the selective
hA3R antagonist VUF5574 were investigated (Fig. 2). The
selective A3R agonist Cl-IB-MECA was included for
comparison, next to adenosine and IPA. As expected,
adenosine and IPA inhibited cAMP production to a similar
extent when added at 10 μM, whereas Cl-IB-MECA had a
more potent effect. Inclusion of ADA abolished the effect
of adenosine, whereas IPA and Cl-IB-MECAwere insensi-
tive to the enzyme. Modulation of the second messenger
Fig. 1 Competition binding experiment on RBL-2H3 cell membranes
endogenously expressing the rat A3R. IPA displaced [
125I]-AB-MECA
from the rat A3R with a Ki value of 4.69±0.20 μM( N=3). Data from
one representative experiment are shown. Incubation was 1 h at 37°C
in 50 mM Tris/ HCl, 10 mM MgCl2 (pH 7.7)
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cantly inhibited by the antagonist VUF5574.
Effect of IPA on the proliferation of tumor cell lines
In view of the reported antitumor effects of agonists for the
A3R, we investigated the effect of IPA on the proliferation
of human prostate carcinoma cells (LNCaP) and rat
hepatocellular carcinoma cells (N1S1). In both tumor cell
lines, IPA inhibited the incorporation of [
3H]-thymidine in a
similar fashion as the reference A3R agonist Cl-IB-MECA
(Figs. 3 and 4). At 10 μM, IPA even had a significantly
greater effect than Cl-IB-MECA on both cell lines (P<
0.01). An approximate EC50 value of 1 μM for IPA was established in the LNCaP cell line, whereas the potency on
the N1S1 cell line seemed somewhat lower. Adenosine, at a
concentration of 25 μM, had only a modest effect on N1S1
Fig. 3 IPA and Cl-IB-MECA have similar antiproliferative effects on
LNCaP tumor cells. IPA and Cl-IB-MECA (0.01–10 μM) both
inhibited proliferation of the human prostate carcinoma cell line
LNCaP . Adenosine (A) (25 μM) had virtually no effect. IPA and Cl-
IB-MECA had significantly larger antiproliferative effects than
adenosine at all concentrations (P<0.01). The effect of IPA increased
significantly at 1 μM compared to the lower concentrations (P<0.01),
and the effect increased further at 10 μM. The effect of Cl-IB-MECA
showed a significant decrease from 0.01 μMt o1μM( P<0.01) and
then significantly increased again at 10 μM( P<0.001). At 10 μM, IPA
had a significantly larger effect than Cl-IB-MECA (P<0.001).
Proliferation was evaluated by incubating a monolayer of serum-
starved cells for 24 h with the compound of interest. For the last 18 h,
1 μCi of [
3H]-thymidine was included in the buffer. Data are means
(±SEM) of three experiments performed in triplicate. Statistical
evaluation was done using an unpaired Student’s t test. **P<0.01;
***P<0.001
Fig. 4 IP A and Cl-IB-MECA have similar antiproliferative effects on
N1S1 tumor cells. IPA and Cl-IB-MECA (0.01–10 μM) both inhibited
proliferation of the rat hepatocellular carcinoma cell line N1S1.
Adenosine (A)( 2 5μM) had only a modest effect. IP A and Cl-IB-
MECA had significantly larger antiproliferative effects than adenosine
(P<0.01), with the exception of 0.01 μMI P Aa n d1μMC l - I B - M E C A .
The effect of IP A increased significantly at 10 μM compared to the
other concentrations (P<0.001). The effect of Cl-IB-MECA showed a
significant decrease from 0.01 to 1 μM and then significantly increased
again at 10 μM( b o t hP<0.001). At 10 μM, IP A had a significantly
larger effect than Cl-IB-MECA (P<0.01). Proliferation was evaluated
by incubating a monolayer of serum-starved cells for 24 h with the
compound of interest. For the last 18 h, 1 μCi of [
3H]-thymidine was
included in the buffer. Data are means (±SEM) of three experiments
performed in triplicate. Statistical evaluation was done using an
unpaired Student’s t test. *P<0.05; **P<0.01; ***P<0.001
Fig. 2 Effect of ADA and A3R antagonist VUF5574 in cAMP
accumulation assays. In CHO cells stably expressed with hA3R,
forskolin-stimulated cAMP production was inhibited by adenosine,
IP A, and Cl-IB-MECA, all at 10 μM. The effects of the concomitant
presence of either the enzyme ADA (0.8 IU/ml) or the antagonist
VUF5574 (10 μM) were also assessed. The cells were incubated for
15 min at room temperature with the ligand(s) of interest±ADA. Then
forskolin was added to the reaction mixture for a further 30 min. Data
are means (±SEM) of four experiments performed in triplicate.
Statistical evaluation was done using an unpaired Student’s t test. *P<
0.05; ***P<0.001
Table 2 Potency of naturally occurring nucleosides on the human
adenosine A3 receptor, as inhibitors of forskolin-stimulated cAMP
production in CHO cells expressing the hA3R
EC50 (μM)
Adenosine 2.9±1.1
N
6-(2-isopentenyl)adenosine (IPA) 2.0±0.7
racemic zeatin riboside 5.8±1.8
EC50 value (N=4, except zeatin riboside N=3) is shown; data are
means (±SEM) of N experiments performed in quadruplicate
458 Purinergic Signalling (2011) 7:453–462proliferation and no effect on the LNCaP cell line. Addition
of ADA inhibitor EHNA (10 μM) did not increase the
adenosine effect in the LNCaP cell line (data not shown),
although it significantly increased the effect of adenosine
on the N1S1 cells, yielding almost full growth inhibition
(see Online resource 1). Addition of EHNA alone, without
adenosine, to N1S1 cells also revealed a 22% basal growth
inhibition, probably mediated by adenosine excreted by the
tumor cells.
Effect of IPA on the proliferation of LNCaP cells
in the presence of the A3R antagonist MRS1523
In a final proliferation assay, we investigated whether
MRS1523, an antagonist with appreciable affinity for both
human and rat A3R, was capable of blocking the effect of
IPA on LNCaP cell proliferation (Fig. 5). The antagonist (at
0.1 and 1 μM) prevented the antiproliferative effect of 0.01
and 0.1 μM IPA. When IPA was added at 1 μM, the
inhibition by MRS1523 was small, although still significant
at higher concentrations. At 10 μM IPA, the antagonist had
no effect.
Determination of IPA in muscle tissue by HPLC
Since IPA is a naturally occurring nucleoside, we investi-
gated its occurrence in muscle tissue. We therefore analyzed
extracts from Wistar rat muscle. The spectra of native and
spiked tissue extracts are shown in Figs. 6a, b, respectively.
From the spiked tissue, 23% of the added IPAwas recovered
in the extract. In the unspiked spectrum, no IPA peak was
observed.
Discussion
In vitro evaluation of IPA activity
We have shown that zeatin riboside and particularly IPA are
ligands for the A3R. These naturally occurring modified
nucleosides bind with submicromolar affinity to the hA3R.
Moreover, the affinity of IPA for A3R is not restricted to the
human ortholog but extends to the rat A3R. In line with
previous findings on N
6-substituted adenosine derivatives
with small alkyl substituents, IPA discriminates between the
two A3R homologs and has a 30-fold higher affinity for the
human A3R[ 17].
Our next step was the evaluation of receptor activation
by IPA, zeatin riboside, and adenosine in cAMP generation
assays. The compounds had similar potencies in the low
micromolar range, with zeatin riboside two- or threefold
less potent than IPA and adenosine.
The potency of adenosine towards the A3Rw a s
classically considered to be in the micromolar range and
rather lower than the potency towards the adenosine A1 and
A2A receptors [18]. In contrast, several more recent
publications report similar potencies of adenosine towards
the A1,A 2B, and A3 subtypes, in the submicromolar range
[19–21]. The affinity and potency that we observed for A3R
activation by adenosine are clearly in better agreement with
the more recent reports. Some care should be taken in the
interpretation of cAMP assay results, however, as receptor
expression levels may have a strong impact on the EC50
values of tested agonists.
Antiproliferative effects of IPA
Interestingly, IPA has antitumor activity both in vitro and in
vivo [22, 23]. In 1975, this compound has been tested in a
pilot clinical trial for leukemia, where it caused remission in
three patients out of 20 [24]. Currently, there is a renewed
interest in the compound; in a recent review, IPA was
defined as an emerging anticancer drug [25]. The molecular
mechanism of the antitumor activity of IPA has not been
elucidated so far.
In view of the well-known role of the A3R in cancer, we
decided to investigate whether the antiproliferative effects
of IPA are mediated by this receptor. IPA inhibits the
proliferation of human prostate cancer cells (LNCaP) and
rat hepatocellular cancer cells (N1S1) to a similar extent as
the A3R reference agonist Cl-IB-MECA, which has nano-
molar affinity at the receptor. These effects may be
mediated by the A3R which is highly expressed in N1S1
cells and probably also in LNCaP cells [12, 26]. The
potency of IPA in this assay seems somewhat lower in the
rat cell line than in the human cell line; this would be in line
with the difference in affinity of IPA towards the rat and
Fig. 5 The antiproliferative effect of IPA is partly blocked by A3R
antagonist MRS1523. The selective A3R antagonist MRS1523 (0.01–
1 μM) blocked the effect of low concentrations (0.01–0.1 μM) of IPA
on human prostate carcinoma (LNCaP) cells. MRS1523 did not inhibit
the effect of high concentrations of IPA (1–10 μM). Proliferation was
evaluated by incubating a monolayer of serum-starved cells for 24 h
with the compound of interest. For the last 18 h, 1 μCi of [
3H]-
thymidine was included in the buffer. Data are means (±SEM) of three
experiments performed in triplicate. Statistical evaluation was done
using an unpaired Student’s t test. **P<0.01; ***P<0.001
Purinergic Signalling (2011) 7:453–462 459human A3R. At 10 μM, IPA is significantly more active
than Cl-IB-MECA in both cell lines.
The A3R antagonist MRS1523 was able to completely
inhibit the effect of low concentrations of IP A (10 and
100 nM) but not higher concentrations (1 and 10 μM). The
affinity of MRS1523 for the hA3R is approximately sixfold
higher compared to IP A [27]. Therefore, it may be that the
antiproliferative effect of higher concentrations of IP A is not
mediated by the A3R but by a different mechanism. A3R-
independent antiproliferative effects of high concentrations
of A3R agonists, including Cl-IB-MECA and IB-MECA,
have previously been observed [28–30]. For example,
30 μM Cl-IB-MECA inhibited growth of leukemia cell lines
HL-60 and MOLT-4 in the presence of antagonists MRS1523
(10 μM) or MRS1220 (5 μM) [28]. Furthermore, Cl-IB-
MECA and IB-MECA, but also adenosine, 2-chloro-
adenosine, and 3′-deoxyadenosine, had antiproliferative
effects on breast cancer cell lines lacking A3Rm R N A[ 29].
Involvement of other adenosine receptor subtypes was
excluded. Suggested pathways for these effects include
downregulation of the estrogen receptor α [29], upregulation
of death receptor Fas [28], and downregulation of cyclins D1
and E2 together with dephosphorylation of ERK1/2 [30]. It
should be noted that the concentrations used in these reports
are between 10 and 100 μM (even 500 μM for adenosine).
The A3R-independent effect of IP A seems to occur even at
1 μM, so it may be a significantly more potent anticancer
agent than the other agonists that have been assessed. At 10
and 100 nM IP A, the antiproliferative effect was entirely
blocked by antagonist MRS1523, so at these low IP A
concentrations, the effect seems entirely A3R dependent.
Plasma concentrations of IP Awere not reported in the pilot
clinical trial on leukemia patients [24, 31]. However, they are
expected to be very low since IP A is metabolized very fast
[31]. After IP A enters the circulation, more than 50% is
excreted in urine in the first 4 h, mostly in metabolized form.
Fig. 6 HPLC analysis of rat
muscle extract detects no IPA.
Comparison of rat muscle tissue
spiked with IPA (b) and
unspiked muscle extract (a) tis-
sue shows that IPA, which is
eluted at 34.2 min in the spiked
tissue, cannot be detected in the
blank tissue
460 Purinergic Signalling (2011) 7:453–462Metabolites include N
6-(3-methyl-hydroxybutylamino)pu-
rine, hypoxanthine, adenine, and several N
6-alkylated
adenines and N-alkylated xanthines [31].
Origin and levels of endogenously occurring IPA
IPA and zeatin riboside are widely studied plant cytokinins
controllingvariousprocessesinplantgrowthanddevelopment
[32, 33]. The nucleosides are also components of tRNA, but
only IPA has been found in mammalian tRNA [33, 34]. Free
IPA is probably present in the mammalian cytoplasm, since
its precursor N
6-(2-isopentenyl)adenosine-3-monophosphate
has been identified in several cell lines [35]. Unchanged IPA
has been detected in human urine at an average amount of
50 μgp e rd a y[ 36]. Although levels of IPA and zeatin
riboside in grains, vegetables, and fruits at the moment of
consumption could not readily be extracted from the
literature, these foods might be exogenous sources of these
compounds. Tuberous roots, such as (sweet) potatoes, seem
especially likely sources [37, 38]. Furthermore, ingested or
residential bacteria in the gut may provide additional
cytokinins [33]. In plants, free zeatin riboside is in the trans
conformation, but tRNA is a source of cis-zeatin riboside.
Most likely, the cis-isomer has the higher affinity for the A3R,
since the trans-isomer is less active than the racemate
(Table 1). However, cis-zeatin riboside is not commercially
available and was therefore not tested in our study.
Colocalization and thus interaction of the proposed
nucleoside ligands and the A3R may occur at the cellular
membrane or, keeping in mind that A3R has a nuclear
localization signal, in or at the nucleus [39]. A3R localized
in colon could interact with IPA and zeatin riboside from
exogenous sources [40].
Detection of endogenous IP A
We have previously reported that an unknown A3R agonist
with antitumor properties is excreted by muscle cells [13].
Since IPA activates A3R and has antiproliferative proper-
ties, the compound might qualify as this unknown factor.
We used HPLC to investigate its presence in commercial
cow, pork, and chicken meat, but detected no IPA. Since the
freshness and storage conditions of commercial meat may
not be ideal, we then switched to fresh rat muscle tissue.
Again, IPA could not be detected, nor did we detect peaks
of IPA metabolites. It is therefore unlikely that IPA is the
muscle-derived A3R agonist we observed previously [13].
Conclusion
Inconclusion,wehaveshownthatbothIP Aandzeatinriboside
bind selectively to the A3R. Moreover, we provide evidence
that the antiproliferative effect of low concentrations of IPA is
mediated by the A3R. Higher concentrations of the compound
seem to have a potent A3R-independent antitumor effect. It is,
however, unlikely that IP A is the previously reported muscle-
derived antiproliferative A3R agonist, since it could not be
detected in rat muscle. More research is needed to elucidate
the putative physiological roles of IPA and the importance of
the A3R for the antitumor action of IPA.
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